Affordable Access

Publisher Website

Design of the Trial to Assess Chelation Therapy (TACT)

Authors
Journal
American Heart Journal
0002-8703
Publisher
Elsevier
Volume
163
Issue
1
Identifiers
DOI: 10.1016/j.ahj.2011.10.002
Disciplines
  • Design

Abstract

TACT is an National Institutes of Health–sponsored, randomized, double-blind, placebo-controlled, 2 × 2 factorial clinical trial testing the benefits and risks of 40 infusions of a multicomponent disodium EDTA chelation solution compared with placebo and of an oral, high-dose multivitamin and mineral supplement. TACT has randomized and will follow up 1,708 patients for an average of approximately 4 years. The primary end point is a composite of all-cause mortality, myocardial infarction, stroke, coronary revascularization, and hospitalization for angina. A 900-patient substudy will examine quality-of-life outcomes. The trial is designed to have >85% power to detect a 25% relative reduction in the primary end point for each treatment factor. Enrollment began in September 2003 and was completed in October 2010.

There are no comments yet on this publication. Be the first to share your thoughts.